Some prostate tumors transition from being glandular to more nerve-like in response to drugs that block the androgen receptor; a new preclinical study examines the underlying mechanisms and uncovers a promising countermeasure.

Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not.

Trial will evaluate the safety and efficacy of histotripsy against liver tumors at eight U.S. sites

ApoE has known roles in cardiovascular disease and Alzheimer’s, but was not previously implicated in pancreatic cancer.

The findings in human cells and animal models suggest potential approaches to improve immunotherapy treatment against cancer.

Approach opens a new avenue to study the biology of acute leukemia and for the development new drugs.

Stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models.

Vaccines and other policies could help keep in check a disease that’s becoming increasingly common worldwide.

Using next-generation sequencing, the UPSeq test assesses 15 biomarkers to find aggressive prostate cancer that can be missed by biopsies or imaging tests.

MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.

Study findings support the recent FDA approval of the immunotherapy agent for patients whose cancers have high number of mutations.

Why you should consider participating in a clinical trial and what to expect from the experience.

Scientists have long sought to target the interaction between the proteins p53 and Mdm2 in tumor cells, but their interaction in immune cells may be just as important.

The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.

Breast cancer stem cells from patients with different racial and ethnic backgrounds showed important differences in activation of immune response-related genes in mouse models.